Chinese (SSE) Pharma Industry Analysis

Industry Valuation and Performance

Has the Chinese Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 21 Jul 2026	CN¥2.8t	CN¥767.7b	CN¥70.0b	34.2x	39.6x	3.6x
Thu, 18 Jun 2026	CN¥2.4t	CN¥769.6b	CN¥69.7b	33.2x	35x	3.2x
Sat, 16 May 2026	CN¥2.8t	CN¥769.8b	CN¥69.7b	37.1x	39.9x	3.6x
Mon, 13 Apr 2026	CN¥2.9t	CN¥771.1b	CN¥67.8b	34.2x	43.4x	3.8x
Wed, 11 Mar 2026	CN¥2.9t	CN¥767.1b	CN¥68.8b	33.4x	42.4x	3.8x
Fri, 06 Feb 2026	CN¥3.0t	CN¥765.4b	CN¥68.4b	34.9x	43.3x	3.9x
Sun, 04 Jan 2026	CN¥3.0t	CN¥765.2b	CN¥68.2b	32.6x	43.3x	3.9x
Tue, 02 Dec 2025	CN¥3.1t	CN¥766.3b	CN¥68.2b	35.2x	45.8x	4.1x
Thu, 30 Oct 2025	CN¥3.2t	CN¥770.7b	CN¥69.5b	35.7x	45.4x	4.1x
Sat, 27 Sep 2025	CN¥3.2t	CN¥770.8b	CN¥66.6b	34.3x	48.4x	4.2x
Mon, 25 Aug 2025	CN¥3.3t	CN¥774.9b	CN¥66.9b	38.5x	50x	4.3x
Wed, 23 Jul 2025	CN¥3.1t	CN¥780.0b	CN¥71.4b	35.6x	43.9x	4x
Fri, 20 Jun 2025	CN¥2.8t	CN¥780.1b	CN¥71.3b	31.8x	39.2x	3.6x
Sun, 18 May 2025	CN¥2.7t	CN¥786.0b	CN¥71.7b	29.8x	37.7x	3.4x
Tue, 15 Apr 2025	CN¥2.6t	CN¥802.7b	CN¥77.4b	27.5x	33.7x	3.3x
Thu, 13 Mar 2025	CN¥2.5t	CN¥800.1b	CN¥75.2b	30.5x	33.8x	3.2x
Sat, 08 Feb 2025	CN¥2.5t	CN¥800.2b	CN¥75.6b	28.2x	33.1x	3.1x
Mon, 06 Jan 2025	CN¥2.5t	CN¥799.8b	CN¥75.6b	28.2x	32.8x	3.1x
Wed, 04 Dec 2024	CN¥2.7t	CN¥799.8b	CN¥75.6b	32.9x	36.4x	3.4x
Fri, 01 Nov 2024	CN¥2.6t	CN¥799.6b	CN¥75.5b	28.8x	35x	3.3x
Sun, 29 Sep 2024	CN¥2.5t	CN¥798.6b	CN¥76.3b	27.9x	32.7x	3.1x
Tue, 27 Aug 2024	CN¥2.3t	CN¥804.4b	CN¥78.4b	25.6x	29.2x	2.8x
Thu, 25 Jul 2024	CN¥2.3t	CN¥804.8b	CN¥76.5b	26.5x	30x	2.9x
Sat, 22 Jun 2024	CN¥2.4t	CN¥805.5b	CN¥74.6b	28x	32.7x	3x
Mon, 20 May 2024	CN¥2.8t	CN¥821.7b	CN¥77.5b	30.4x	35.5x	3.3x
Wed, 17 Apr 2024	CN¥2.6t	CN¥828.6b	CN¥80.3b	25.8x	31.8x	3.1x
Fri, 15 Mar 2024	CN¥2.7t	CN¥832.1b	CN¥80.6b	28.2x	33x	3.2x
Sun, 11 Feb 2024	CN¥2.5t	CN¥831.3b	CN¥81.1b	25x	30.3x	3x
Tue, 09 Jan 2024	CN¥2.7t	CN¥830.9b	CN¥79.7b	30.4x	33.9x	3.2x
Thu, 07 Dec 2023	CN¥2.9t	CN¥827.9b	CN¥79.7b	31.1x	36x	3.5x
Sat, 04 Nov 2023	CN¥2.8t	CN¥820.5b	CN¥78.7b	31.3x	35.4x	3.4x
Mon, 02 Oct 2023	CN¥2.8t	CN¥824.9b	CN¥78.6b	32.3x	35.8x	3.4x
Wed, 30 Aug 2023	CN¥2.7t	CN¥820.6b	CN¥78.8b	30.2x	33.7x	3.2x
Fri, 28 Jul 2023	CN¥2.8t	CN¥810.8b	CN¥76.9b	32.3x	36.3x	3.4x

Current Industry PE

Investors are relatively neutral on the Chinese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 37.4x.

The industry is trading close to its 3-year average PS ratio of 3.5x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have declined 3.1% per year over the last three years.
Meanwhile revenues have remained mostly flat.
This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Chinese Healthcare industry?


CN Market	-6.17%
Healthcare	2.33%
Pharma	2.15%
Pharma	2.15%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
688506 Sichuan Biokin PharmaceuticalLtd	CN¥336.20	12.2% +CN¥15.1b	11.3%	PS54.5x
600436 Zhangzhou Pientzehuang Pharmaceutical	CN¥140.02	11.5% +CN¥8.7b	-29.5%	PE44.4x
300765 CSPC Innovation Pharmaceutical	CN¥41.62	10.8% +CN¥5.7b	-24.0%	PS24.7x
002422 Sichuan Kelun Pharmaceutical	CN¥47.80	6.7% +CN¥4.8b	36.5%	PE48.4x
688578 Shanghai Allist Pharmaceuticals	CN¥127.42	8.3% +CN¥4.4b	32.8%	PE23.7x

Company

Last Price

Valuation

688506 Sichuan Biokin PharmaceuticalLtd

CN¥336.20

12.2%
+CN¥15.1b

11.3%

PS54.5x

600436 Zhangzhou Pientzehuang Pharmaceutical

CN¥140.02

11.5%
+CN¥8.7b

-29.5%

PE44.4x

300765 CSPC Innovation Pharmaceutical

CN¥41.62

10.8%
+CN¥5.7b

-24.0%

PS24.7x

002422 Sichuan Kelun Pharmaceutical

CN¥47.80

6.7%
+CN¥4.8b

36.5%

PE48.4x

688578 Shanghai Allist Pharmaceuticals

CN¥127.42

8.3%
+CN¥4.4b

32.8%

PE23.7x

Sichuan Biokin Pharmaceutical Co., Ltd. Announces Second Approval of Iza-Bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

SystImmune announced that its parent company, Sichuan Biokin Pharmaceutical Co. Ltd., has received regulatory approval from China's National Medical Products Administration (NMPA) for iza-bren (izalontamab brengitecan) for the treatment of adult patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose disease has progressed following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This marks the second approved indication for iza-bren in China following its recent approval for recurrent or metastatic nasopharyngeal carcinoma (NPC), further establishing iza-bren as a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) with broad clinical potential across multiple solid tumors. The approval is supported by results from the pivotal PANKU-Esophagus01 (BL-B01D1-305) study. The study met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS), demonstrating statistically significant and clinically meaningful improvements versus chemotherapy, while maintaining a manageable safety profile. The results were previously presented during an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Key results from the PANKU-Esophagus01 study included: Median overall survival of 9.8 months with iza-bren versus 7.2 months with chemotherapy (HR=0.64, 95% CI: 0.49–0.83; p=0.0004). Median progression-free survival by BICR of 4.2 months with iza-bren versus 2.0 months with chemotherapy (HR:0.50; 95% CI: 0.40-0.63; pAbout PANKU-Esophagus01. PANKU-Esophagus01 (BL-B01D1-305) is a randomized, open-label, multicenter phase 3 clinical trial evaluating iza-bren versus investigator's choice chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma who experienced disease progression following platinum-based chemotherapy plus PD-1/PD-L1 inhibitor therapy. A total of 497 patients were randomized across 80 study centers in China. The study met both dual primary endpoints of progression-free survival and overall survival at the pre-specified interim analysis. Esophageal cancer is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer-related death worldwide. Esophageal squamous cell carcinoma (ESCC) is the predominant histologic subtype globally and accounts for approximately 90% of esophageal cancer cases in China. Despite advances in first-line treatment with platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors, most patients with recurrent or metastatic ESCC ultimately experience disease progression and have historically faced limited treatment options in the second-line setting, with poor response rates and a median overall survival of less than one year. SystImmune, in collaboration with BMS outside of China, is developing iza-bren (BL-B01D1), a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren's dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren's therapeutic novel Topo1i payload is released causing cytotoxic stress that leads to cancer cell death.

Chinese (SSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Sichuan Biokin Pharmaceutical Co., Ltd. Announces Second Approval of Iza-Bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

New minor risk - Share price stability

Investor sentiment improves as stock rises 28%

002422: Higher Future P/E Assumptions And Completed Buyback Will Support Upside

Now 23% overvalued after recent price rise

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Betta Pharmaceuticals Publishes Study of Ensartinib as Postoperative Adjuvant Therapy in the New England Journal of Medicine

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 19%

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026

Yunnan Baiyao Group Co.,Ltd to Report First Half, 2026 Results on Aug 29, 2026

ApicHope Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026

Fujian Cosunter Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026

Shanghai Allist Pharmaceuticals Co., Ltd. to Report First Half, 2026 Results on Aug 20, 2026